Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

异环磷酰胺 阿霉素 医学 养生 顺铂 化疗 丝裂霉素C 泌尿科 外科 内科学 胃肠病学
作者
J H Edmonson,Louise Ryan,Ronald H. Blum,John S. Brooks,Masanori Shiraki,Stephen Frytak,David Parkinson
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:11 (7): 1269-1275 被引量:518
标识
DOI:10.1200/jco.1993.11.7.1269
摘要

PURPOSE: This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin. PATIENTS AND METHODS: Between December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus doxorubicin 60 mg/m2), or treatment C (mitomycin 8 mg/m2 plus doxorubicin 40 mg/m2 plus cisplatin 60 mg/m2). RESULTS: Of 262 assessable patients, 74 (29%) achieved objective tumor regression. Objective regression occurred in 20% of the 90 patients who received doxorubicin alone (complete remission [CR] rate, 2%), in 34% of the 88 who received ifosfamide plus doxorubicin (CR rate, 3%), and in 32% of the 84 who received mitomycin plus doxorubicin plus cisplatin (CR rate, 7%). With grade 3 or greater myelosuppression in 53% of group A, 80% of group B, and 55% of group C, regimen B was significantly more myelosuppressive than either regimen A or C (P = .01) with two, three, and one treatment-related deaths, respectively. Synovial sarcomas were responsive to ifosfamide plus doxorubicin, especially among patients younger than 40 years of age. CONCLUSION: Ifosfamide plus doxorubicin produced a significantly higher regression rate (P = .03) than did doxorubicin alone; however, this was achieved at a level of myelosuppression significantly more intense than that produced by the single agent or by the three-drug combination. Mitomycin, doxorubicin, and cisplatin also appeared to be more active than the single agent; however, at a myelosuppression level similar to that of doxorubicin alone, this trend (P = .07) did not attain the usual level for significance. No significant survival differences were observed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沃铁完成签到,获得积分10
刚刚
刚刚
刚刚
ddd发布了新的文献求助10
1秒前
1秒前
中科路2020完成签到,获得积分10
1秒前
1秒前
1秒前
老实天奇发布了新的文献求助50
1秒前
在水一方的应助被菠菜采纳,获得10
2秒前
2秒前
null的应助被迅速风华采纳,获得10
2秒前
2秒前
2秒前
查资料完成签到 ,获得积分10
3秒前
傲娇的鹰完成签到,获得积分10
3秒前
迷路访云完成签到,获得积分10
3秒前
丹丹发布了新的文献求助10
3秒前
AllenLau1031完成签到,获得积分10
4秒前
4秒前
mm发布了新的文献求助10
5秒前
初景的应助被幽默灵萱采纳,获得20
5秒前
Crystal发布了新的文献求助10
5秒前
高贵的小甜瓜完成签到,获得积分10
5秒前
爆米花的应助被嘻嘻采纳,获得10
5秒前
充电宝的应助被Dafu采纳,获得200
6秒前
Orange的应助被欧阳铭采纳,获得10
6秒前
面包超人发布了新的文献求助10
6秒前
mm发布了新的文献求助50
7秒前
LF完成签到,获得积分10
7秒前
JamesPei的应助被听话的迎荷采纳,获得10
7秒前
7秒前
爆米花的应助被迷路访云采纳,获得10
7秒前
7秒前
xiangoak发布了新的文献求助20
8秒前
mm发布了新的文献求助10
8秒前
8秒前
古炮完成签到,获得积分10
8秒前
l林钟完成签到 ,获得积分10
9秒前
April发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Spec 401: Standards for Jet Fuel Facility and Equipment Commissioning and Flushing at Airports, 2026.1 (Original Issue) 1000
Spec 103: Standard for Jet Fuel Quality Control at Airports, Revision 2026.1 1000
Mathematical models in hydrology 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Erzählte Gnade 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8087351
求助须知:如何正确求助?哪些是违规求助? 9500773
关于积分的说明 21422136
捐赠科研通 7658871
什么是DOI,文献DOI怎么找? 3403680
关于科研通互助平台的介绍 2532410
邀请新用户注册赠送积分活动 2442073